Revolution starts with evolution. Progress regarding emesis has been highlighted by the American Society of Clinical Oncology Committee (https://www.asco.org/about-asco/press-center/news-releases/asco-50th-anniversary-poll-names-top-5-advances-past-50-years) as one of the five leading advances in cancer during the past 50 years. A new generation of antiemetics is approved by the FDA every 10 years leading to a significant enhancement of a no emesis response rate for patients undergoing chemotherapy. We must remember that 100% of cancer-treated patients were impacted by emesis in the seventies, whereas today, ‘only’ 10%–20% of patients are affected [1, 2]. Before the development of setrons (5HT3 receptor antagonists) there was a daily fight by the patient against vomiting. The NK1 inhibitor’s development has radically altered the face of the emesis battle and we can now effectively assess nausea and individual risk factors [3–5].

中文翻译：

---

新的止吐药：面对当前的挑战。

革命始于进化。关于呕吐的进展已由美国临床肿瘤学会委员会强调（https://www.asco.org/about-asco/press-center/news-releases/asco-50th-anniversary-poll-names-top-5 -过去50年）是过去50年中癌症的五个领先进展之一。FDA每10年批准一次新一代的止吐药，从而显着提高接受化疗的患者的无呕吐反应率。我们必须记住，在七十年代，接受癌症治疗的患者中有100％受呕吐的影响，而如今，只有10％–20％的患者受到了呕吐的影响[1、2]。在开发强壮剂（5HT3受体拮抗剂）之前，患者每天都在与呕吐作斗争。